Sarepta Therapeutics IncFind Ratings Reports
SAREPTA THERAPEUTICS INC's gross profit margin for the first quarter of its fiscal year 2017 has significantly decreased when compared to the same period a year ago. Even though it increased sales and net income significantly, the company was unable to grow at a faster pace than its industry competitors. SAREPTA THERAPEUTICS INC is extremely liquid. Currently, the Quick Ratio is 5.39 which clearly shows the ability to cover any short-term cash needs. SRPT managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 208.81% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY17||Q1 FY16|
|Net Sales ($mil)||16.34||0.0|
|Net Income ($mil)||84.09||-59.77|
|Balance Sheet||Q1 FY17||Q1 FY16|
|Cash & Equiv. ($mil)||390.31||139.85|
|Total Assets ($mil)||511.53||213.36|
|Total Debt ($mil)||13.69||20.98|
|Profitability||Q1 FY17||Q1 FY16|
|Gross Profit Margin||-228.69||0.0|
|Return on Assets||-24.12||-102.28|
|Return on Equity||-28.75||-157.05|
|Debt||Q1 FY17||Q1 FY16|
|Share Data||Q1 FY17||Q1 FY16|
|Shares outstanding (mil)||54.94||45.77|
|Div / share||0.0||0.0|
|Book value / share||7.81||3.04|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1883726.0||2552435.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Conducting a second comparison, its price-to-book ratio of 4.54 indicates a premium versus the S&P 500 average of 3.09 and a significant discount versus the industry average of 11.09. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, SAREPTA THERAPEUTICS INC proves to trade at a discount to investment alternatives within the industry.
|SRPT NM||Peers 41.96||SRPT NM||Peers 43.61|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
SRPT's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
SRPT's P/CF is negative making the measure meaningless.
|SRPT NM||Peers 26.44||SRPT NA||Peers 0.54|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
SRPT's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|SRPT 4.54||Peers 11.09||SRPT 47.11||Peers -9.68|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
SRPT is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
SRPT is expected to have an earnings growth rate that significantly exceeds its peers.
|SRPT 89.58||Peers 172.46||SRPT 1636.87||Peers 462.34|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
SRPT is trading at a significant discount to its industry on this measurement.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
SRPT has a sales growth rate that significantly exceeds its peers.